HEM파마, myLAB Analysis Service Full-Process Automation Equipment Investment of 21.81818181 Billion Won Decided

HEM파마 (376270) announced on June 19 that it has decided to invest in new facilities for myLAB's analysis service full-process automation, including automation equipment and dedicated software. The investment of 21.81818181 billion won represents 41.84% of its equity capital of 52.14854634 billion won. The board of directors approved the resolution on June 19, 2026, with three outside directors present and no auditor attendance. The investment period spans from June 19, 2026, to March 31, 2027. The company noted potential adjustments to investment scope and duration based on future progress and management conditions, with execution authority delegated to the CEO. As of June 19, HEM파마's stock closed at 51,000 won, up 0.99% from the prior day. Recent results (as of December 2025) show total assets of 518 billion won, liabilities of 466 billion won, equity of 52 billion won, revenue of 130 billion won, operating loss of 156 billion won, and net loss of 237 billion won. The firm, listed on KOSDAQ since December 30, 2016, is a natural science and engineering R&D company.